These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 2570758

  • 1. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR.
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [Abstract] [Full Text] [Related]

  • 2. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD.
    Clin Ther; 1994 Jul; 16(3):490-504. PubMed ID: 7923316
    [Abstract] [Full Text] [Related]

  • 3. Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
    Silke B, Guy S, Humphreys JE.
    J Hum Hypertens; 1992 Jun; 6(3):221-5. PubMed ID: 1352828
    [Abstract] [Full Text] [Related]

  • 4. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
    Luther RR, Glassman HN, Sperzel WD, Steinberg FJ, Horton JK, Jordan DC.
    J Hypertens Suppl; 1986 Dec; 4(5):S494-7. PubMed ID: 2883273
    [Abstract] [Full Text] [Related]

  • 5. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S, Monk JP.
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [Abstract] [Full Text] [Related]

  • 6. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study.
    Shionoiri H, Gotoh E, Ito T, Hata T, Iwatsubo H, Takegawa K, Ogihara T, Mikami H, Ikegami H, Otsuka A.
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S91-5. PubMed ID: 7908168
    [Abstract] [Full Text] [Related]

  • 7. [Pressure and metabolic effects of terazosin in essential hypertension].
    Valle R, Semplicini A, Serena L, Gebbin A, Fontebasso A, Gerardi G, De Toni R, Pessina AC.
    Cardiologia; 1994 Jun; 39(6):421-4. PubMed ID: 7923256
    [Abstract] [Full Text] [Related]

  • 8. Terazosin: a new alpha adrenoceptor blocking drug.
    Achari R, Laddu A.
    J Clin Pharmacol; 1992 Jun; 32(6):520-3. PubMed ID: 1353083
    [Abstract] [Full Text] [Related]

  • 9. [Effect of enalapril and terazosin on lipid metabolism in patients with essential arterial hypertension and accompanying hypercholesterolemia].
    Ponikowski P, Hańczycowa H, Sebzda T, Jurga M, Spring A, Rotter A, Jordanek P.
    Wiad Lek; 1993 Apr; 46(7-8):250-4. PubMed ID: 7902632
    [Abstract] [Full Text] [Related]

  • 10. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with untreated essential hypertension.
    Lytle T, Coles S, Waite MA.
    J Hum Hypertens; 1991 Feb; 5(1):35-8. PubMed ID: 1674964
    [Abstract] [Full Text] [Related]

  • 11. Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.
    Holtzman JL, Kaihlanen PM, Rider JA, Lewin AJ, Spindler JS, Oberlin JA.
    Arch Intern Med; 1988 Mar; 148(3):539-43. PubMed ID: 3277569
    [Abstract] [Full Text] [Related]

  • 12. Blood pressure and lipid lowering effects of terazosin.
    Rosenthal J.
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():85-9; discussion 90-1. PubMed ID: 2575179
    [Abstract] [Full Text] [Related]

  • 13. Alpha 1-blockers, their antihypertensive efficacy and effects on lipids and lipoprotein.
    Kincaid-Smith P.
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():75-83. PubMed ID: 2575178
    [Abstract] [Full Text] [Related]

  • 14. Metabolic changes during antihypertensive therapies.
    Krone W, Nägele H.
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():69-73; discussion 74. PubMed ID: 2575177
    [Abstract] [Full Text] [Related]

  • 15. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
    Hernández Hernández R, Angeli-Greaves M, Carvajal AR, Guerrero Pajuelo J, Armas Padilla MC, Armas-Hernández MJ.
    Am J Hypertens; 1996 May; 9(5):437-44. PubMed ID: 8735174
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular effects of short-term selective alpha 1-adrenergic blockade with terazosin in patients with essential hypertension.
    Beretta-Piccoli C, Ferrier C, Weidmann P.
    J Hypertens Suppl; 1985 Dec; 3(3):S231-4. PubMed ID: 2908818
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial.
    Liu H, Liu P, Mao G, Chen G, Wang B, Qin X, Na Y, Liu Z, Wang X, Xu X.
    Urology; 2009 Jul; 74(1):130-6. PubMed ID: 19371934
    [Abstract] [Full Text] [Related]

  • 18. The effects of terazosin and methyclothiazide on blood pressure and serum lipids.
    Luther RR, Glassman HN, Estep CB, Maurath CJ, Jordan DC.
    Am Heart J; 1989 Apr; 117(4):842-7. PubMed ID: 2564723
    [Abstract] [Full Text] [Related]

  • 19. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B.
    Curr Med Res Opin; 2001 Apr; 17(1):8-17. PubMed ID: 11464450
    [Abstract] [Full Text] [Related]

  • 20. Effects of terazosin on serum lipid levels in hypertensive blacks.
    Luther RR, Klepper MJ, Maurath CJ, Glassman HN, Achari R, Laddu AR.
    J Hum Hypertens; 1990 Apr; 4(2):154-6. PubMed ID: 1971028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.